RESUMEN
Objective To observe the clinical effect of lansoprazole enteric -coated tablets combined with flupentixol and melitracen in the treatment of erosive gastritis with anxiety .Methods Eighty patients with erosive gastritis complicated with anxiety were selected , and they were randomly divided into control group ( n =40 ) and observation group( n=40) according to the digital table .The control group was treated with lansoprazole enteric -coa-ted tablets.The observation group received lansoprazole enteric -coated tablets combined with flupentixol and melitra-cen.Hamming anxiety scale ( HAMA ) and Hamilton depression scale ( HAMD ) were used to evaluate in the two groups before and after treatment .The changes of HAMA and HAMD scores were compared between the two groups .Results Before treatment,the scores of abdominal pain ,bloating,pantothenic acid and belching had no statistically significant differences between the two groups (all P>0.05).After treatment for 4 weeks,the scores of abdominal pain,bloating, pantothenic acid and belching in the observation group were ( 0.63 ±0.12 ) points, ( 0.43 ± 0.11)points,(0.30 ±0.11)points and (0.31 ±0.14)points,respectively,which were lower than those in the control group [(1.42 ±0.18)points,(1.08 ±0.15)points,(0.79 ±0.16)points,(0.98 ±0.25)points] (t=15.396, 13.285,16.758,17.492,all P<0.05).The scores of HAMA and HAMD in the observation group were (12.15 ± 2.51)points and (14.32 ±2.51) points,respectively,which were lower than those in the control group [(19.84 ± 2.65)points,(19.84 ±3.17)points](t=20.151,21.841,all P<0.05).There was no statistically significant differ-ence in the incidence rate of adverse reactions between the two groups after treatment for 4 weeks (P >0.05) .Conclusion Lansoprazole enteric -coated tablets combined with flupentixol and melitracen in the treatment of erosive gastritis with anxiety can relieve anxiety and depression ,improve clinical symptoms and treatment effect .
RESUMEN
OBJECTIVE:To observe therapeutic efficacy and safety of paroxetine combined with flupentixol melitracen in the treatment of post-stroke major depressive disorder(PSMDD). METHODS:120 PSMDD patients were randomly divided into group A(40 cases),group B(40 cases)and group C(40 cases). All patients received routine stroke treatment;group A was additionally given Paroxetine hydrochloride enteric-coated sustained-release tablet 25 mg orally,once a day;group B was additionally given Flu-pentixol melitracen tablet 20 mg orally twice a day;group C was additionally given Paroxetine hydrochloride enteric-coated sus-tained-release tablet (same usage and dosage as group A)+flupentixol melitracen (same usage and dosage as group B). Three groups were treated for 28 d. Clinical efficacies of 3 groups were observed as well as NIHSS,ADL,HADM,SS-QOL score,hos-pitalization stay and the occurrence of ADR. RESULTS:Total response rate of group C was significantly higher than those of group A and B;hospitalization day was significantly less than those of group A and B,with statistical significance(P0.05). There was no statistical significance in the incidence of ADR among 3 groups (P>0.05). Before treatment,there was no statistical significance in NIHSS,ADL,HADM,SS-QOL score among 3 groups(P>0.05). After 10,28 d of treatment,NIHSS,HADM,SS-QOL score of 3 groups were significantly lower than before, above indexes were decreased gradually as time,and the group C were lower than the group A and B;ADL score of 3 groups were significantly higher than before,this index was increased gradually as time,and the group C were lower than the group A and B with statistical significance (P0.05). CONCLUSIONS:Based on routine treatment,paroxetine combined with flupentixol melitracen in the treatment of PSMDD can relieve neurologic function injury,improve depression condition and the quality of life without increasing the occurrence of ADR.
RESUMEN
Objective To investigate the clinical curative effect of flupentixol/melitracen (deanxit) combined with mosapride citrate in the treatment of functional dyspepsia.Methods The clinical data of 240 patients with functional dyspepsia were collected,According to different treatment method,they were divided into two groups,120 patients of the control group were treated with mosapride citrate combined with omeprazole,120 patients of the observation group were treated with deanxit combined with mosapride citrate.One course of treatment was 4 weeks.After one course of treatment,the clinical curative effects and adverse reactions of the two groups were evaluated.Results After treatment,the abdominal distension,abdominal pain,early satiety,belching and other symptoms scores of the two groups were significantly lower compared with before treatment,the differences were statistically significant (all P ＜ 0.05).After treatment,the abdominal distension,abdominal pain,early satiety,belching and other symptoms scores of the observation group were significantly lower than those in the control group,the differences were statistically significant(all P ＜ 0.05).The clinical total effective rate of the observation group was 90.8％,which was significantly higher than 67.5 ％ of the control group,the difference was statistically significant (x2 =8.432,P ＜ 0.05).Before and after treatment,the liver and kidney function and blood in the urine routine examination in the two groups had no significant changes.The incidence rate of adverse reactions of the observation group was 11.67％,which of the control group was 15.83 ％,there was no statistically significant difference (x2 =0.911,P ＞ 0.05).Conclusion Deanxit combined with mosapride citrate in the treatment of functional dyspepsia is one of the important method,and its clinical effect is satisfactory,relatively safe,it is worthy of popularization and application.
RESUMEN
Objective To evaluate the clinical efficacy of flupentixol melitracen joint esomeprazole, mosapride in the treatment of refractory gastroesophageal reflux disease.Methods 80 patients with refractory gastroe-sophageal reflux disease were randomly divided into control group and observation group,40 cases in each group.Two groups of patients were given oral esomeprazole and mosapride treatment,the observation group was treated with flu-pentixol melitracen on the basis of control group.4 weeks for a course of treatment,patients were treated for 2 courses. The clinical efficacy of the two groups,the depression and anxiety RDQ score before and after treatment,the adverse reactions were recorded.Results The total effective rate of the observation group was 82.50%,which was signifi-cantly higher than 70.00% of the control group,the difference was statistically significant (χ2 =3.660,P 0.05). After treatment,the RDQ in symptom score and frequency integrator of the control group were (8.12 ±0.89)points, (7.70 ±1.00)points,compared with before treatment,the differences were significant (t =4.70,6.37,all P <0.05),and those of the observation group were (5.21 ±0.45)points,(4.71 ±0.78)points,which were significantly lower than those of the control group,the differences were statistically significant (t =1.81,1.81,all P <0.05).After treatment,the SAS score and SDS score of control group were (49.12 ±5.89)points,(50.30 ±6.00)points,com-pared with before treatment,the differences were significant (t =1.81,1.81,all P <0.05),and those of the observa-tion group were (41.21 ±5.45),(43.71 ±5.78),which were significantly lower than the control group (t =2.30, 1.91,all P <0.05).During the treatment,the adverse events in the two groups were similar,no serious adverse reac-tions were observed.Conclusion Flupentixol melitracen joint esomeprazole,mosapride in the treatment of refractory gastroesophageal reflux disease has significant clinical effect,can effectively improve the clinical symptoms of depres-sion and anxiety scores,and without significant adverse reactions,it is worthy of clinical application.
RESUMEN
Objective To explore the clinical efficacy and safety of rabeprazole in combined with flupentixol melitracen in treatment of non -erosive gastroesophageal reflux disease with anxiety and depression.Methods 84 cases with non -erosive gastroesophageal reflux disease with anxiety and depression of outpatient and inpatient admitted from October 2012 -October 2013 and they were randomly divided into two groups according to the order,all had 42 cases.The control group was given rabeprazole treatment,observation group used flupentixol melitracen treat-ment on the basis of the control group.The clinical efficacy and the occurrence of adverse reactions of the two groups were compared.Results The total effective rate of the observation group was 95.24%,which was significantly higher than 76.19% in the control group,the difference was significant (χ2 =11.20,P 0.05 ).Conclusion Rabe-prazole in combined with flupentixol melitracen in treatment of non -erosive gastroesophageal reflux disease with anxi-ety and depression had good effect,and the adverse reactions were mild and safe.
RESUMEN
Objective To investigate the short and long-term effects of flupentixol-melitracen after percu-taneous coronary intervention( PCI) .Methods 86 patients with coronary heart disease who would be given PCI were randomly divided into 43 cases of the study group and 43 cases of the control group.The control group was given conventional treatment after surgery, the study group was given flupentixol -melitracen on the basis of the control group.After one course,the mental status changes and short-term effect were observed.All the patients had been follow-up for 1 year to observe the occurrence of cardiovascular events.Results After one course,the HAMA and HAMD in the study group and the control group were (7.46 ±2.53) points and (15.74 ±3.16) points,(8.03 ± 1.97)points and (16.42 ±3.67)points respectively,which in the study group were lower than the control group (t=13.413,13.208, all P <0.01 ) .The total effective rate of the study group was 97.67%, which was higher than 81.40%of the control group (χ2 =6.081,P<0.05).During follow-up,the incidence rate of adverse cardiovascular events in the study group was 6.67%,which was lower than 42.86%of the control group (χ2 =9.564,P<0.05). Conclusion The flupentixol-melitracen can effectively improve anxiety and depression, improve the recent thera-peutic effect of PCI,reduce the incidence of cardiovascular events,which worthy of promotion after PCI.
RESUMEN
Objective To investigate the clinical effects and the quality of life of flupentixol-melitracen or paroxetine hydrochloride in treatment of the breast cancer patients with anxiety and depression after chemotherapy.Methods 135 breast cancer patients with anxiety and depression after chemotherapy were selected from November 2012 to January 2014 in the hospital.They were randomly divided into the treatment group ( n=68 ) and control group ( n =67 ).The control group were treated by paroxetine hydrochloride treatment, and the treatment group were treated by flupentixol-melitracen.The anxiety, depression and its impact on quality of life of patients were observed between two groups.Results After treatment, the HAMD score and HAMA score decreased significantly in two groups (P<0.05), HAMD score and HAMA score in treatment group after treatment significantly decreased compared with control group (P<0.05).After treatment, the WHOQOL-BREF score of mental health status scale of subjective feeling, the physiological domain, domain score levels in treatment group significantly increased (P<0.05), however, the quality of life of subjective feeling, social relationship and environment domains showed no significant difference.Compared with pre-treatment, only the health status of subjective feeling levels in control group post-treatment significantly increased (P<0.05).The mental health status scale of subjective feeling, the physiological domain, domain score levels in treatment group significantly decreased compared with control group ( P<0.05 ).The adverse reactions of treatment group were 5 cases (7.35%), which was significantly lower than 24 cases (35.82%) of control group(χ2 =16.22,P <0.05).Conclusion Flupentixol-melitracen combined with paroxetine hydrochloride has an obvious clinical effect in treatment of anxiety and depression in patients with breast cancer after chemotherapy.It could effectively control their anxiety and depression, and improve the quality of life of patients.It is worthy of clinical popularization and application.
RESUMEN
Objective To assess the therapeutic effects of flupentixol and melitracen tablets combined with Saccharomyces boulardii on patients with diarrhea-predominant irritable bowel syndrome (IBS) accompanied with anxiety and depression.Methods This multi-center,randomized,prospective study enrolled 84 patients with diarrhea-predominant IBS who were divided into combined treatment group (42 patients) and control group (42 patients).Saccharomyces boulardii was administrated in both of the groups,and flupentixol and melitracen was added in combined treatment group.The treatment course was four weeks.The gastrointestinal symptoms and mood disorders were evaluated before treatment,one week and four weeks after treatment.Adverse reactions were also observed.Chi-square test was performed for statistical analysis.Results At the end of one week after treatment,the efficacy rates of gastrointestinal symptoms improvement of combined treatment group and control group were 31.0％ (13/42) and 23.8％ (10/42),and there was no statistically significant difference (P＞0.05).At the end of four weeks after treatment,the efficacy rate of gastrointestinal symptoms improvement of combined treatment group was 92.5％ (37/40),which was higher than that of control group (73.2％,30/41),and the difference was statistically significant (x2 =5.291,P =0.037).At the end of one week after treatment,the efficacy rates of Hamilton Depression Scale score improvement of combined treatment group and control group were 31.6％ (12/38) and 12.1％ (4/33),and there was no statistically significant difference (P＞0.05).At the end of four weeks after treatment,the efficacy rates of Hamilton Depression Scale score improvement of combined treatment group was 63.9％ (23/36),which was higher than that of control group (34.4％,11/42),and the difference was statistically significant (x2 =6.433,P=0.043).At the end of one week and four weeks after treatment,the efficacy rates of Hamilton Depression Scale score improvement of combined treatment group were 35.7％ (15/42) and 80.0％ (32/40),which were higher than those of control group (15.4％,6/39 and 34.2％,13/38),and the differences were statistically significant (x2 =9.759,P=0.007; x2 =17.105,P＜0.01).One week after treatment,the adverse events rates of combined treatment group and control group were 4.8％ (2/42) and 4.8％ (2/42) ; four weeks after treatment,the adverse events rates of combined treatment group and control group were 2.5％ (1/40) and 2.4％ (1/41).There was no statistically significant difference in adverse events rates between two groups (both P＞0.05).Conclusions Flupentixol and melitracen combined with Saccharomyces boulardii treatment could not only improve the anxiety and depression symptoms of patients with diarrhea-predominant IBS,but also effectively improve gastrointestinal symptoms.The efficacy of combined treatment is better than monotherapy Saccharomyces boulardii alone treatment.
RESUMEN
OBJECTIVE:To observe clinical efficacy and safety of mosapride combined with flupentixol melitracen in the treat-ment of elderly functional heartburn. METHODS:106 elderly patients with functional heartburn in accordance with Rome IIIstan-dard were randomly divided into control group(52 cases)and treatment group(54 cases). The control group was treated with Mo-sapride dispersible tablets 5mg,tid,orally;the treatment group was additionally given Flupentixol melitracen tablets(containing flu-pentixol 0.5 mg and melitracen 10 mg),qd,on the basis of control group. Therapeutic efficacy of 2 groups were observed after 4 weeks. Hamilton anxiety scale(HAMA),Hamilton depressive scale(HAMD) and symptom score were conducted before and after treatment. RESULTS:The total effective rate of treatment group and control group were 87.0%and 53.8%;with statistical signifi-cance(P<0.05);there was statistical significance in symptom score,HAMA score and HAMD score between 2 groups after treatment (P<0.01). No severe ADR was found in 2 groups. CONCLUSIONS:Mosapride combined with flupentixol melitracen is safe and ef-fective in the treatment of elderly functional heartburn.
RESUMEN
Objective To investigate the clinical efficacy and safety of tolterodine combined with flupentixol melitracen in the treatment of women with overactive bladder (OAB).Methods 84 female patients with OAB were chosen and randomly divided into the observation group and the control group.42 cases in observation group were treated with tolterodine combined with flupentixol melitracen.42 cases in control group were only treated with tolterodine.The clinical efficacy was recorded and compared after treatment for 4 weeks.Results The total effective rate of the observation group was higher than the control group (95.24％ vs 76.19％,x2 =6.291,P ＜ 0.05).The 24h frequency of urination,the average 24h number of incontinence episodes,initial urinate capacity and maximum bladder pressure capacity had statistically significant differences between the two groups (all P ＜ 0.05).Conclusion Tolterodine combined with flupentixol melitracen in the treatment of women with OAB has advantages of short course of treatment,excellent efficacy,and few side effects.
RESUMEN
Objective To investigate the clinical outcomes of flupenthixol melitracen on refractory asthma with anxiety and/or depression.Methods 105 patients with refractory asthma,who were given asthma controlled test (ACT) and comprehensive hospital anxiety and depression scale (HAD)test,were randomly classified into control group and treatment group,the former used recommended classical drugs in the consensus,Salmeterol Xinafoate and Fluticasone Propionate and Montelukast;while the latter used above therapy combining flupentixol melitrace.HAD score,ACT score and pulmonary function were applied to assess therapeutic effect.Results In 105 cases of refractory asthma patients,75 patients were complicated with anxiety and/or depression,with prevalence of 71.42％.With the alleviation of anxiety and/or depression,the degree of asthma controlled was improved.After treatment,HAD score of the treatment group was lower that of control group((10.67±2.32) scores vs (11.94±3.02) scores,t=2.06,P＜0.05),ACT score in treatment group was much higher than that of control group((14.54± 3.14) scores vs (11.25±3.06)scores,t=4.59,P＜0.01),there were statistical significance in FEV1％ pre between two groups ((55.29±5.72) vs (43.36±7.13),t=8.02,P＜0.01).Conclusion Antidepressant treatment can alleviate anxiety and/or depression,improve the clinical curative effect of refractory asthma and help to improve lung function.
RESUMEN
Objective To evaluate the efficacy of deanxit in treatment of post-stroke depression (PSD).Methods60 patients with PSD were randomly divided into treatment group ( plus with deanxit) and control group (plus with estazolam necessarily). At the baseline and at 2 weeks,4 weeks, 8 weeks after the treatment, the efficacy was assessed with HAMD, SSS, and ADL rating scale respectively. Results After 2,4,8 weeks treatment, HAMD and SSS scores of the treatment group significantly decreased compared with the control group ( all P ＜ 0. 01 ), and ADL scores of the treatment group increased significantly compared with the control group ( P ＜ 0. 01 ). Conclusion Deanxit could effectively relieve depressing symptoms and neurological impairment of PSD, and clinical side effects of deanxit were less. Deanxit was suitable for acute phase and long-term maintenance therapy in PSD.
RESUMEN
OBJECTIVE:To evaluate the efficacy of Flupentixol Melitracen for functional dyspepsia (FD) of seamen. METHODS: A total of 139 seamen with FD were enrolled,of whom,59 who had no abnormality in abnormal psychologic test were assigned to Group C,another 80 with abnormality in abnormal psychologic test were randomized to Group A or Group C. All the 3 groups received Mosapride,but Group A received additional Flupentixol Melitracen for 8 weeks. Before and after treatment,scores of gastrointestinal symptom rating scale (GSRS),self-rating anxiety scale (SAS) and self-rating depressive scale(SDS) were compared. RESULTS: The standard scores of SAS and SDS in FD seamen were higher than the domestic norms(P